Related Experiment Video

Updated: Jun 14, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K

Role of PLK4 inhibition in cancer therapy

Kishore Banik1, Thomas J Hayman2

  • 1Department of Therapeutic Radiology, Yale University School of Medicine, 15 York Street, New Haven, CT, 06510, USA.

Cancer Metastasis Reviews
|June 13, 2025
PubMed

Insights

Polo-like kinase 4 (PLK4) is crucial for centrosome duplication and genomic stability. Targeting PLK4 with inhibitors shows promise for cancer therapy, especially when combined with other treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Genomic instability is a key feature of cancer, linked to tumor progression and treatment resistance.
  • Centrioles and centrosomes are vital for maintaining genomic stability.
  • Polo-like kinase 4 (PLK4) regulates centrosome duplication and its overexpression drives tumorigenesis.

Purpose of the Study:

  • To review the functions of PLK4 in normal and cancerous processes.
  • To evaluate the therapeutic potential of targeting PLK4 in cancer.
  • To discuss emerging combination strategies involving PLK4 inhibitors.

Main Methods:

  • Literature review of PLK4 functions and its role in cancer.
  • Analysis of preclinical and clinical data on PLK4 inhibitors.
  • Exploration of combination therapies with DNA-damaging agents and immunotherapies.

Main Results:

  • PLK4 overexpression is associated with advanced cancer and poor outcomes.
  • PLK4 inhibitors are being investigated in preclinical and clinical settings.
  • Combinations of PLK4 inhibitors with other therapies may enhance efficacy.

Conclusions:

  • PLK4 is a significant therapeutic target in oncology.
  • PLK4 inhibitors represent a promising avenue for cancer treatment.
  • Further research into combination therapies is warranted to maximize therapeutic benefits.
Keywords:
CancerCentrosome amplificationDNA-damaging therapyPLK4PLK4 inhibitors

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K